Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 4 February 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Completion of the transfer of shares in 2 equity-method affiliates is expected to be delayed until the fiscal year ending March 2027; the likelihood of recognizing impairment losses on diabetes treatment product marketing rights and other assets has increased as the pharmaceutical business is being streamlined; and the likelihood of partially reversing deferred tax assets has increased.
The likelihood of recognizing impairment losses on diabetes treatment product marketing rights and other assets has increased, but the amount was not disclosed. The likelihood of partially reversing deferred tax assets has also increased, but the amount was not disclosed.
| Item | Details |
|---|---|
| Net Sales | ¥860,000 million → ¥860,000 million |
| Operating profit | ¥5,000 million → △75,000～△85,000 |
| Profit attributable to owners of the parent | △10,000 → △85,000～△95,000 |
| Net income per share | △51.85 → △440.76～△492.62 |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 4 February 2026 |
| Previous-period results | Revenue 1,005,471 million yen / Business profit 27,594 million yen / Operating profit -71,828 million yen / Profit for the period attributable to owners of the parent 28,347 million yen / Basic earnings per share 147.15 yen and sen |
| Reason for the revision | Completion of the transfer of shares in 2 equity-method affiliates is expected to be delayed until the fiscal year ending March 2027; the likelihood of recognizing impairment losses on diabetes treatment product marketing rights and other assets has increased as the pharmaceutical business is being streamlined; and the likelihood of partially reversing deferred tax assets has increased. |
| Details and amount of extraordinary loss | The likelihood of recognizing impairment losses on diabetes treatment product marketing rights and other assets has increased, but the amount was not disclosed. The likelihood of partially reversing deferred tax assets has also increased, but the amount was not disclosed. |
| Dividend forecast revision | No revision. For the fiscal year ending March 2026, a dividend of ¥50 per share is planned, including an interim dividend of ¥25. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Completion of the transfer of shares in 2 equity-method affiliates is expected to be delayed until the fiscal year ending March 2027; the likelihood of recognizing impairment losses on diabetes treatment product marketing rights and other assets has increased as the pharmaceutical business is being streamlined; and the likelihood of partially reversing deferred tax assets has also increased.